Chris Lau

Chris Lau

InvestorPlace Contributor

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

IAC/InteractiveCorp Stock Will Shake off This Dip Nicely

By Chris Lau, InvestorPlace Contributor

Despite the fact that IAC stock is close to yearly highs, the company continues to trade at a big discount to fair value. That may change as investors take notice to its future prospects.

Video-Centric Content Has Momo Inc (ADR) Stock on the Mend

By Chris Lau, InvestorPlace Contributor

Momo is pushing multiple social tools that encourage online chat, adding video-centric content to fuel user growth. MOMO stock is on the mend

Is Gilead Sciences, Inc. Stock Still a Solid Value Play?

By Chris Lau, InvestorPlace Contributor

Despite a weak fourth-quarter, Gilead Sciences (GILD) stock still has deep value. If its drug studies play out, it could return to growth sooner than expected.

Why Qualcomm, Inc. Stock Won’t Trade Over $80 Anytime Soon

By Chris Lau, InvestorPlace Contributor

Qualcomm is trading well below the offer price made by Broadcom and is in a royalty payment dispute with Apple. For now, QCOM stock will trade at a discount.

A Breakout in Aurinia Pharmaceuticals Inc May Be Imminent

By Chris Lau, InvestorPlace Contributor

The downtrend in shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) may end soon -- not from the renewed interest in biotech stocks but because of Aurina’s upcoming…

Load More